12:00 AM
 | 
Aug 19, 2013
 |  BioCentury  |  Emerging Company Profile

SynapDx: Autism early warning

SynapDx aims to predict autism risk earlier with RNA profiling in toddlers

SynapDx Corp. aims to use RNA sequencing to lower the age of diagnosis for autism spectrum disorder into early toddlerhood, which would improve the odds of success for behavioral therapy.

The company has raised more than $33 million to develop an RNA-based screening tool for early detection of autism spectrum disorder. The company is recruiting a large prospective trial of a gene expression signature it believes can predict the risk of developing ASD.

The target population is children as young as 18 months who do not appear to be developing normal social and cognitive functions, said President and CEO Stanley Lapidus.

He said early identification of children likely to develop ASD could help pediatricians and parents decide on a suitable course of action sooner than is currently possible.

"ASD has a median age of diagnosis of 4.5 years old. Experts believe that as a child gets older, the ability to improve outcomes through behavioral therapy diminishes...

Read the full 765 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >